{
    "symbol": "OM",
    "quarter": 2,
    "year": 2022,
    "date": "2022-08-05 15:51:02",
    "content": " You may proceed with your question. Again, it just depends on our provider's ability to help, train -- identify patients train patients and then get them home over the next six months, over the next remainder of the year. We -- what I remarked on was, we've actually started to see our pipeline mix shift in let's say, in the mid-Q2 time forward to mostly hospitals that are very, very motivated to use Tablo in order to in-source dialysis because it generates even more dramatic cost reduction. You may proceed with your question. You may proceed with your question. So Nabeel one of your responses earlier I believe to Suraj's question, it sounds like it's just a few million dollars maybe $5 million to $7 million of the $40 million cut versus our last guidance is going to come from the home side, just a much smaller revenue base. Another example of impact we had a number -- have a number of contracts that we would call enterprise solutions that are covering the use of Tablo in the acute setting sometimes in the sub-acute setting, sometimes in the home setting all health systems centric. You may proceed with your question."
}